VEGF-B Antibody (MM0008-7B43): sc-101581
- VEGF-B Antibody (MM0008-7B43) is a mouse monoclonal IgG1, cited in 1 publications, provided at 100 µg/ml
- raised against recombinant VEGF-B167167 of human origin
- recommended for detection of VEGF-B167 and VEGF-B186 of human origin by WB, IP and IF; non cross-reactive with VEGF, VEGF-C or VEGF-D
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for VEGF-B Antibody (MM0008-7B43). This work is in progress.
VEGF-B Antibody (MM0008-7B43) is a mouse monoclonal IgG1 antibody that detects VEGF-B in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). VEGF-B plays a crucial role in angiogenesis, which is the formation of new blood vessels from pre-existing ones, a process vital for normal physiological functions as well as tumor growth and metastasis. VEGF-B is predominantly expressed in heart and skeletal muscle tissues, where VEGF-B is often co-expressed with other members of the vascular endothelial growth factor family, such as VEGF. Notably, VEGF-B exists in two isoforms, VEGF-B167 and VEGF-B186, which are generated through alternative splicing and may have distinct biological activities. The interaction of VEGF-B with receptors, particularly Flt-1, is essential for mediating angiogenic effects, making VEGF-B a significant target for research in cancer biology and therapeutic interventions. The genes encoding human VEGF-B are located on chromosome 11q13, highlighting genetic significance in the context of vascular development and pathology. With an ability to facilitate the study of VEGF-B′s role in both normal and disease states, anti-VEGF-B antibody (MM0008-7B43) is an invaluable tool for researchers investigating the mechanisms of angiogenesis and implications in various diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
VEGF-B Antibody (MM0008-7B43) References:
- VEGF-B selectively regenerates injured peripheral neurons and restores sensory and trophic functions. | Guaiquil, VH., et al. 2014. Proc Natl Acad Sci U S A. 111: 17272-7. PMID: 25404333
- VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis. | Huang, D., et al. 2016. Sci Rep. 6: 26059. PMID: 27189805
- VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. | Räsänen, M., et al. 2016. Proc Natl Acad Sci U S A. 113: 13144-13149. PMID: 27799559
- VEGF-B promotes recovery of corneal innervations and trophic functions in diabetic mice. | Di, G., et al. 2017. Sci Rep. 7: 40582. PMID: 28091556
- VEGF-A and VEGF-B Coordinate the Arteriogenesis to Repair the Infarcted Heart with Vagus Nerve Stimulation. | Lv, YX., et al. 2018. Cell Physiol Biochem. 48: 433-449. PMID: 30016789
- VEGF-B signaling impairs endothelial glucose transcytosis by decreasing membrane cholesterol content. | Moessinger, C., et al. 2020. EMBO Rep. 21: e49343. PMID: 32449307
- VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions. | Llorián-Salvador, M., et al. 2020. Invest Ophthalmol Vis Sci. 61: 35. PMID: 32945843
- Co-expression of VEGF-B and FLT-1 correlates with malignancy and prognosis of gastric cancer. | Ma, Y., et al. 2021. Biomark Med. 15: 481-488. PMID: 33856262
- Increased Serum VEGF-B Level Is Associated With Renal Function Impairment in Patients With Type 2 Diabetes. | Wei, Y., et al. 2022. Front Endocrinol (Lausanne). 13: 862545. PMID: 35399943
- VEGF-B targeting by aryl hydrocarbon receptor mediates the migration and invasion of choriocarcinoma stem-like cells. | Tan, Q., et al. 2022. Cancer Cell Int. 22: 221. PMID: 35773697
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VEGF-B Antibody (MM0008-7B43) | sc-101581 | 100 µg/ml | $316.00 |